Literature DB >> 15072472

Pituitary stalk thickening and primary central nervous system lymphoma.

M Capra1, D Wherrett, S Weitzman, P Dirks, C Hawkins, E Bouffet.   

Abstract

We report a 14-year-old girl in whom a diagnosis of primary central nervous system lymphoma was confirmed while receiving growth hormone (GH) for GH deficiency, detected after presenting with short stature. MRI revealed an enhancing and thickened pituitary stalk with absence of the normal bright signal in the posterior pituitary. Regular MRI surveillance detected progression of the neurohypophyseal changes 13 months into GH treatment. Biopsy confirmed this to be B-cell large cell lymphoma. This case highlights the diagnostic and management challenges inherent in treating such children.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072472     DOI: 10.1023/b:neon.0000021863.06620.48

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

1.  Risk of leukemia in children treated with human growth hormone: review and reanalysis.

Authors:  D B Allen; A C Rundle; D A Graves; S L Blethen
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  Growth hormone receptor and serum binding protein: purification, cloning and expression.

Authors:  D W Leung; S A Spencer; G Cachianes; R G Hammonds; C Collins; W J Henzel; R Barnard; M J Waters; W I Wood
Journal:  Nature       Date:  1987 Dec 10-16       Impact factor: 49.962

3.  Primary cerebral lymphoma: an association with craniopharyngioma or cadaveric growth hormone therapy?

Authors:  G M Forbes; A K Cohen
Journal:  Med J Aust       Date:  1992-07-06       Impact factor: 7.738

4.  Intracranial malignant lymphomas: clinicopathological study of 26 autopsy cases.

Authors:  K Onda; K Wakabayashi; R Tanaka; H Takahashi
Journal:  Brain Tumor Pathol       Date:  1999       Impact factor: 3.298

5.  Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents.

Authors:  S L Mootha; A J Barkovich; M M Grumbach; M S Edwards; S E Gitelman; S L Kaplan; F A Conte
Journal:  J Clin Endocrinol Metab       Date:  1997-05       Impact factor: 5.958

6.  Thickened pituitary stalk on magnetic resonance imaging in children with central diabetes insipidus.

Authors:  J Leger; A Velasquez; C Garel; M Hassan; P Czernichow
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

7.  Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan.

Authors:  Y Nishi; T Tanaka; K Takano; K Fujieda; Y Igarashi; K Hanew; T Hirano; S Yokoya; K Tachibana; T Saito; S Watanabe
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

Review 8.  Leukemia and other malignancies among GH users.

Authors:  S Watanabe; S Mizuno; L H Oshima; Y Tsunematsu; J Fujimoto; A Komiyama
Journal:  J Pediatr Endocrinol       Date:  1993 Jan-Mar

9.  Composite germ cell tumor and B-cell non-Hodgkin's lymphoma arising in the sella turcica.

Authors:  Riccardo Valdez; Paul McKeever; William G Finn; Stephen Gebarski; Bertram Schnitzer
Journal:  Hum Pathol       Date:  2002-10       Impact factor: 3.466

10.  Risk of leukemia after treatment with pituitary growth hormone.

Authors:  J E Fradkin; J L Mills; L B Schonberger; D K Wysowski; R Thomson; S J Durako; L L Robison
Journal:  JAMA       Date:  1993-12-15       Impact factor: 56.272

View more
  9 in total

1.  Primary pituitary lymphoma in an immunocompetent patient: a rare clinical entity.

Authors:  Yaxiong Li; Yuekang Zhang; Jianguo Xu; Ni Chen
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

2.  Unusual primary central nervous system lymphoma location involving the fourth ventricle and hypothalamus.

Authors:  Michaela Cellina; Vincenza Fetoni; Pierluigi Baron; Marcello Orsi; Giancarlo Oliva
Journal:  Neuroradiol J       Date:  2015-04-13

3.  Hypothalamic dysfunction in a patient with primary lymphoma of the central nervous system.

Authors:  Darko Antic; Mihajlo Smiljanic; Jelena Bila; Snezana Jankovic; Milena Todorovic; Bosko Andjelic; Biljana Mihaljevic
Journal:  Neurol Sci       Date:  2011-08-06       Impact factor: 3.307

Review 4.  Primary hypothalamic lymphoma in a patient with systemic lupus erythematosus: case report and review of the literature.

Authors:  Antonella Biasiotta; Alessandro Frati; Maurizio Salvati; Antonino Raco; Maurizio Fazi; Alessandro D'Elia; Giorgio Cruccu
Journal:  Neurol Sci       Date:  2010-06-29       Impact factor: 3.307

5.  Primary central nervous system lymphoma mimicking pituitary apoplexy: case report.

Authors:  Stacey Quintero Wolfe; Brian Hood; Jennifer Barker; Ronald J Benveniste
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 6.  Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma.

Authors:  Mutsuko Yasuda; Nobu Akiyama; Sachio Miyamoto; Masahiro Warabi; Yumiko Takahama; Mari Kitamura; Fumiatsu Yakushiji; Hiroyuki Kinoshita
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

7.  Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus.

Authors:  Brian Thomas Layden; Steve Dubner; Daniel J Toft; Peter Kopp; Sean Grimm; Mark E Molitch
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

8.  Primary lymphoma of the pituitary gland: an unusual cause of hemianopia in an immunocompetent patient.

Authors:  Pg Rainsbury; A Mitchell-Innes; Nj Clifton; Hs Khalil
Journal:  JRSM Short Rep       Date:  2012-08-17

9.  Primary Pituitary Lymphoma in Immunocompetent Patients: A Report on Two Case Studies and the Review of Literature.

Authors:  Lian Duan; Jie Liu; Yan Zhang; Lijia Cui; Xiao Zhai; Boju Pan; Lin Lu; Hui Pan; Yong Yao; Huijuan Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-04       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.